Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort

Table 1 Baseline characteristics of the glucagon like peptide-1 receptor agonist group and control group, n (%)

Variables	GLP-1RA group (n = 139)	Control group (n = 278)	P value
Age (years)	52.52 ± 12.65	51.96 ± 13.20	0.872
Sex (male/female, male %)	77/62, 55.40	166/112, 59.71	0.431
Duration of diabetes (years)	10.25 ± 9.15	9.70 ± 8.51	0.726
FBG (mmol/L)	7.81 ± 2.18	7.72 ± 1.97	0.993
2hPBG (mmol/L)	8.55 ± 2.50	8.56 ± 2.21	0.914
HbA1c (%)	6.91 ± 1.20	6.88 ± 1.21	0.956
UACR (mg/g)	170.16 ± 560.78	116.68 ± 408.78	0.053
eGFR (mL/min/1.73 m2)	85.51 ± 23.60	85.91 ± 22.91	0.937
Body weight (kg)	79.66 ± 13.77	71.18 ± 13.83	< 0.001
BMI (kg/m2)	28.11 ± 4.17	25.08 ± 3.65	< 0.001
UACR grades
< 30 mg/g	53 (66.25)	94 (79.66)	0.072
30-300 mg/g	8 (10.00)	10 (8.47)
> 300 mg/g	19 (23.75)	14 (11.86)
BMI grades
18-24 kg/m2	0 (0.00)	6 (3.02)	< 0.001
24-28 kg/m2	20 (14.39)	69 (34.67)
28-35 kg/m2	55 (39.57)	85 (42.71)
> 35 kg/m2	64 (46.04)	39 (19.60)

FBG: Fasting blood glucose; PBG: Prandial blood glucose; HbA_1c: Glycosylated hemoglobin; UACR: Urinary albumin-creatinine ratio; eGFR: Estimated glomerular filtration rate; BMI: Body mass index; GLP-1Ras: Glucagon like peptide-1 receptor agonists.